Articles

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Cardinal Health, Dublin, OH, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology/Oncology, Presbyterian/Columbia University Medical Center, New York, NY, USA
Hematology/Oncology, Duke University, Durham, NC, USA
Hematology and Medical Oncology, Cleveland Clinic, OH, USA
Pharmacy, Ernest Mario School of Pharmacy, New Brunswick, NY, USA;Hematology/Oncology, John Theurer Cancer Center, Hackensack, NY, USA
Hematology/Oncology, John Theurer Cancer Center, Hackensack, NY, USA
Hematology/Oncology, Georgetown University Hospital, Washington DC, USA
Hematology/Oncology, University of Rochester Medical Center, NY, USA
Hematology/Oncology, Penn State Milton S Hershey Medical Center, PA, USA
Lymphoma, Celgene Corp, Summit, NY, USA
Hematology/Oncology, John Theurer Cancer Center, Hackensack, NY, USA
Hematology/Oncology, Penn State Milton S Hershey Medical Center, PA, USA
Hematology/Oncology, Lankenau Hospital, Wynnewood, PA, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology and Medical Oncology, Cleveland Clinic, OH, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology/Oncology, Presbyterian/Columbia University Medical Center, New York, NY, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Division of Hematology and Oncology, University of Rochester, NY, USA
Hematology/Oncology, Georgetown University Hospital, Washington DC, USA
Vol. 103 No. 5 (2018): May, 2018 https://doi.org/10.3324/haematol.2017.182907